Highlights
- Market Cap
- $80.84M
- Enterprise Value
- $49.96M
- EPS (TTM)
- $2.42
- PE Ratio
- 2.66
- Gross Profit (TTM)
- -$91.00K
- EBITDA (TTM)
- $19.08M
- Year Range
- $1.35 - $8.05
- Target Price
- $13.00
- ROA (TTM)
- 48.27%
- ROE (TTM)
- 70.98%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Q32 Bio Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Q32 Bio Inc (QTTB) has returned 93.37% so far this year and 289.09% over the past 12 months.
Q32 Bio Inc
- 1D
- 8.81%
- 1M
- 40.79%
- YTD
- 93.37%
- 6M
- 224.24%
- 1Y
- 289.09%
- 3Y*
- -29.78%
- 5Y*
- -48.26%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Mar 28, 2018, QTTB's average daily return is +0.01%, while the average monthly return is -0.09%.
Historically, 46% of months were positive and 54% were negative. The best month was Jul 2024 with a return of +112.1%, while the worst month was Dec 2024 at -87.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, QTTB closed higher 47% of trading days. The best single day was Jul 10, 2025 with a return of +119.9%, while the worst single day was Dec 11, 2024 at -75.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 16.87% | 17.53% | 40.79% | 93.37% | |||||||||
| 2025 | -11.92% | -25.08% | -27.31% | -3.03% | 8.12% | -13.87% | 48.99% | -22.97% | 15.79% | 41.92% | -22.06% | 51.60% | -3.49% |
| 2024 | 10.20% | 37.31% | 2.90% | 60.80% | -6.93% | -29.61% | 112.14% | 14.18% | 2.62% | 5.85% | -43.02% | -87.22% | -68.57% |
| 2023 | 24.60% | -3.18% | -32.24% | -7.77% | 2.81% | -9.39% | 57.06% | -13.67% | -2.50% | -11.11% | -48.94% | 14.50% | -51.75% |
| 2022 | 2.20% | -6.18% | -12.89% | -45.39% | -11.45% | 34.01% | 9.14% | 8.84% | -31.20% | -7.45% | 3.36% | -18.18% | -65.38% |
| 2021 | 7.62% | -11.60% | -12.38% | -28.06% | -1.92% | 9.49% | -12.52% | 13.05% | 9.46% | -27.19% | -11.87% | -27.92% | -67.76% |
Benchmark Metrics
Q32 Bio Inc has an annualized alpha of -12.63%, beta of 1.12, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since March 29, 2018.
- This stock participated in 158.91% of S&P 500 Index downside but only -34.45% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -12.63%
- Beta
- 1.12
- R²
- 0.05
- Upside Capture
- -34.45%
- Downside Capture
- 158.91%
Return for Risk
Risk / Return Rank
QTTB ranks 91 for risk / return — in the top 91% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Q32 Bio Inc (QTTB) and compare them to a chosen benchmark (S&P 500 Index).
| QTTB | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.66 | 0.90 | +0.76 |
Sortino ratioReturn per unit of downside risk | 3.61 | 1.39 | +2.22 |
Omega ratioGain probability vs. loss probability | 1.43 | 1.21 | +0.22 |
Calmar ratioReturn relative to maximum drawdown | 5.39 | 1.40 | +3.99 |
Martin ratioReturn relative to average drawdown | 9.99 | 6.61 | +3.39 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore QTTB risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Q32 Bio Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Q32 Bio Inc was 99.75%, occurring on Jul 7, 2025. The portfolio has not yet recovered.
The current Q32 Bio Inc drawdown is 98.82%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.75% | Apr 8, 2019 | 1570 | Jul 7, 2025 | — | — | — |
| -30.9% | Jul 11, 2018 | 23 | Aug 10, 2018 | 30 | Sep 24, 2018 | 53 |
| -25.93% | Dec 11, 2018 | 9 | Dec 21, 2018 | 42 | Feb 25, 2019 | 51 |
| -19.55% | Oct 1, 2018 | 22 | Oct 30, 2018 | 23 | Dec 3, 2018 | 45 |
| -13.41% | May 7, 2018 | 30 | Jun 18, 2018 | 14 | Jul 9, 2018 | 44 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Q32 Bio Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Q32 Bio Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for QTTB, comparing it with other companies in the Biotechnology industry. Currently, QTTB has a P/E ratio of 2.7. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for QTTB in comparison with other companies in the Biotechnology industry. Currently, QTTB has a P/B value of 1.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |